Ondine Biomedical Inc president and chief technology officer Nicolas Loebel and Matt Ross, vice president of Sales and Marketing joined Steve Darling from Proactive to share exciting news regarding the expansion of Ondine's Steriwave nasal photodisinfection technology within the healthcare sector.
Alberta Health Services has confirmed its decision to expand the use of Steriwave nasal photo-disinfection following promising data from its pilot introduction at the Mazankowski Alberta Heart Institute. The pilot project demonstrated significant reductions in surgical site infections following cardiac surgery.
Ross provided more details about the successful pilot project and shared that the Royal Alexandra Hospital in Edmonton is set to implement Steriwave nasal photo-disinfection before performing 3,000 orthopedic surgeries over the next year.
The interest from hospitals across Canada and internationally has been increasing, leading to faster adoption of the platform.
Loebel also highlighted the latest data from Vancouver General Hospital and UBC Hospital, which showed a remarkable 66.5% reduction in spine surgery infection rates with the pre-surgical use of Steriwave. These findings were presented at the IP2023 Annual conference in Liverpool in October and have been accepted for publication in the Canadian Journal of Surgery.
Contact Details
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.